Sponsored by Drexel University Center for Graduate Studies
Navigating the Brave New Patent World
Wednesday, January 18, 2012
8:45 am - 11:30 am
Registration, breakfast and networking from 8:45-9:00 a.m.
Drexel University, One Capitol Mall, Suite 260, Sacramento, CA 95814
Companies will need to reevaluate their patent application filing strategies and their policies regarding public disclosures of their inventions in view of the shift to first-to-file and the changes to what is considered prior art. Strategies for dealing with competitors’ patent estates will also have to evolve, as will litigation strategies and defenses. In the wake of the Act, the use of reexamination and the new post-grant review procedures may relocate patent battles from the courtrooms of Eastern Texas to the halls of the PTO.
This seminar will focus on practical advice for dealing with the new Act, including:
- Impact of moving to first-to-file on your U.S. patent portfolio, including the enlarged scope of prior art
- Effective use of the post-grant review system, including the availability of stays of litigation for pending post-grant reviews
- Replacement of inter partes reexamination with inter partes review and its impact
- Timetable for transition and effective dates
- Fees and other key changes in patent practice and structure
- Elimination of the best mode defense in litigation
- Significant narrowing of false marking causes of action
Rachel Krevans, Partner, Morrison Foerster, San Francisco
Otis Littlefield, Partner, Morrison Foerster, San Francisco
General Admission: $40; SARTA Members: $25
Price includes free parking for 4 hours at the One Capitol Mall Valet Garage on 2nd Street (valued at $8) and a continental breakfast.
If you are a SARTA member, please email firstname.lastname@example.org for member discount code.
Rachel Krevans, Partner, Morrison-Foerster, San Francisco
For more than 20 years Rachel Krevans has tried patent disputes involving all manner of products in the electronics and biosciences areas. Her work in these industries has involved an assortment of technologies – from DVRs, cable and satellite TV, and computer-phone interfaces, to HIV and cancer treatments, vaccines, and blood and antibody research.
Ms. Krevans's contentious matters often involve some of the most difficult and complex circumstances. Take for example the rare defense jury verdict in favor of her client EchoStar in the Eastern District of Texas in 2007. At the time of the trial, plaintiff Forgent was seeking $205 million in damages. Her winning trial strategy created a new model for defending patent cases in the Eastern District of Texas.
Another recent and complex case involved her client Bayer in a patent infringement matter against Abbott Diabetes Care in the Northern District of California. After Bayer won summary judgment on one of the two patents, the case was quickly reassigned to a new judge, who set a six-week timeline for a trial on the second patent. Bayer won at trial, prevailing on both patents and all asserted claims.
Chambers notes Ms. Krevans as “one of the most thorough, calculating and technically astute IP lawyers around” and says “the powerful scientific mind of Rachel Krevans has impressed clients in the life sciences industry.”
Otis Littlefield, Partner, Morrison-Foerster, San Francisco
Otis Littlefield is a partner in the San Francisco office. His practice focuses on representing life science clients, including biotechnology, pharmaceutical, agricultural biotechnology, and medical device companies.
He specializes in two main areas: intellectual property-related business transactions and patent prosecution, including patent portfolio strategy, management, and evaluation. He has expertise in vaccines and adjuvants, stem cell therapeutics, molecular biology, diagnostics, high throughput screening and microarray technologies, gene therapy, bioinformatics, medical devices, and plant molecular biology and breeding. His practice includes drafting and prosecuting patent applications, including interferences and re-examinations. Dr. Littlefield’s practice also includes conducting due diligence studies in connection with venture capital, private and public financing, and mergers and acquisitions.
In the intellectual property-related business transactions, he has represented a variety of life science companies on a broad range of transactions, including in- and out-licenses, drug discovery and development agreements, clinical trial agreements, manufacture and supply agreements, joint research and development agreements, commercialization agreements, strategic joint ventures, and mergers and acquisitions.
Dr. Littlefield received a B.S. in chemistry and biology from Purdue University and a Ph.D. in molecular and cellular biology from the University of California at Berkeley. His doctoral thesis work focused on structural studies of the eukaryotic heat shock transcription factor binding to DNA. He worked as a post-doctoral research associate at Yale University, where he conducted structural studies of basal transcription initiation of RNA polymerase. Dr. Littlefield received a J.D. from the University of California at Berkeley. He is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.
Registration for SARTA's Leadership Series